SPAS-1 (stimulator of prostatic adenocarcinomaspecific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 9, 2008, Pages 3509-3514

  Fassò, Marcella ^a   Waitz, Rebecca ^c,d   Hou, Yafei ^b   Rim, Tae ^a   Greenberg, Norman M ^e   Shastri, Nilabh ^c   Fong, Lawrence ^b   Allison, James P ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Immunotherapy; Prostatic neoplasms; T cell antigen; TRAMP mice

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; SPAS1 ANTIGEN; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; CANCER VACCINE; CARRIER PROTEIN; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; EPITOPE; LEUKOCYTE ANTIGEN; SH3GLB2 PROTEIN, HUMAN; SH3GLB2 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; DENDRITIC CELL; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ANIMAL; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MOLECULAR GENETICS; T LYMPHOCYTE; TRANSGENIC MOUSE;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; BASE SEQUENCE; CANCER VACCINES; CARRIER PROTEINS; CLONING, MOLECULAR; HUMANS; IMMUNODOMINANT EPITOPES; MALE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; POINT MUTATION; PROSTATIC NEOPLASMS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 42149150398     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0712269105     Document Type: Article

References (36)

1. van der Bruggen P, et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647.
2. Hege KM, Jooss K, Pardoll D (2006) GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int Rev Immunol 25:321-352.
3. Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979) Purification of a human prostate specific antigen. Invest Urol 17:159-163.
4. Vihko P, et al. (1988) Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 236:275-281.
5. Israeli RS, Powell CT, Fair WR, Heston WD (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53:227-230.
6. Fong L, Small EJ (2007) Immunotherapy for prostate cancer. Curr Oncol Rep 9:226-233.
7. Elkord E (2007) Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer Prostatic Dis 10:224-236.
8. Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565-594.
9. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-618.
10. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366.
11. van Elsas A, et al. (2001) Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194:481-489.
12. Foster BA, et al. (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57:3325-3330.
13. Hurwitz AA, et al. (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444-2448.
14. Kwon ED, et al. (1997) Manipulation of T cell Costimulatory and Inhibitory Signals for Immunotherapy of Prostate Cancer. Proc Natl Acad Sci USA 94:8099-8103.
15. Malarkannan S, Mendoza LM, Shastri N (2001) Generation of antigen-specific, lacZ-inducible T cell hybrids. Methods Mol Biol 156:265-272.
16. Gingrich JR, et al. (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096-4102.
17. Eggert AO, et al. (2002) Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur J Immunol 32:122-127.
18. Hermans IF, Daish A, Moroni-Rawson P, Ronchese F (1997) Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunol Immunother 44:341-347.
19. Salucci V, et al. (2005) Adenovirus transduction and culture conditions affect the immunogenicity of murine dendritic cells. Scand J Immunol 62:206-217.
20. Toldbod HE, Agger R, Bolund L, Hokland M (2003) Potent influence of bovine serum proteins in experimental dendritic cell-based vaccination protocols. Scand J Immunol 58:43-50.
21. Lapointe J, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101:811-816.
22. Bainbridge MN, et al. (2006) Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics 7:246.
23. Carinci F, et al. (2003) Genetic portrait of malignant granular cell odontogenic tumour. Oral Oncol 39:69-77.
24. Renneberg H, et al. (1999) Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread. Urol Res 27:23-27.
25. Schmollinger JC, et al. (2003) Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci USA 100:3398-3403.
26. Nair SK, et al. (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6:1011-1017.
27. Heslop HE, Stevenson FK, Molldrem JJ (2003) Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program 331-349.
28. Peoples GE, et al. (2005) Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23:7536-7545.
29. Grossmann ME, Wood M, Celis E (2001) Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines. World J Urol 19:365-370.
30. Kawakami Y, et al. (2004) Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95:784-791.
31. Yang D, et al. (2001) Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61:5857-5860.
32. Drake CG, et al. (2005) Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7:239-249.
33. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465.
34. Matzinger P (1991) The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 145:185-192.
35. Lutz MB, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223:77-92.
36. Fonteneau JF, et al. (2001) Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 258:111-126.